section name header

Pronunciation ⬇

ben-AYE-ze-pril

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also ↑ plasma renin levels and ↓ aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in patients with hypertension.

Pharmacokinetics ⬆ ⬇

Absorption: 37% absorbed after oral administration.

Distribution: Crosses the placenta; enters breast milk in small amounts.

Protein Binding: 95%.

Metabolism/Excretion: Converted by the liver to benazeprilat, the active metabolite; 20% excreted in urine; 11–12% nonrenal (biliary) elimination.

Half-Life: Benazeprilat: 10–11 hr.

Time/Action Profile ⬆ ⬇

(antihypertensive effect)

ROUTEONSETPEAKDURATION
POwithin 1 hr*1–2 wks‡24 hr‡



*After single dose.

‡Chronic dosing.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension

Derm: rash

F and E: hyperkalemia

GI: nausea

GU: impaired renal function

Neuro: fatigue, dizziness, drowsiness, headache

Resp: cough

Misc: ANGIOEDEMA

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Lotensin

Code ⬆

NDC Code